Related to Abbott Pays Biotest $85M Up Front in Deal for Phase II mAb Against RA and Psoriasis

• Qiagen and Abbott Forge Pact on Molecular Tests for HIV, HCV, and HPV
  
• Myriad to Conduct BRCA Mutation Testing for Abbott’s Phase III Study
  
• Sucampo and Abbott One Step Closer to Japanese Approval of Constipation Drug
  
• Abbott and EpiTherapeutics Ally to Develop Epigenetic Cancer Drugs
  
• Abbott to Use Seattle Genetics’ Antibody-Drug Conjugate Platform for $8M Up Front
  
• Abbott to Distribute Biofortuna’s Freeze-Dried HLA-Typing PCR Kits
  
• Alder Earns $15M Milestone from BMS on the Start of Phase IIa Trial with IL-6-Targeting mAb
  
• BMS and Ono Expand Cancer Antibody Deal and Agree to Partner Orencia in Japan
  
• Neurocrine Wins $20M from Abbott Related to Elagolix for Endometriosis
  
• Phase III Trial Confirms Benefits of Abbott’s Humira Against Nonradiographic Axial Spondyloarthritis
  
• Abbott, GSK Add Immunotherapies to Companion Dx Partnership
  
• Abbott Pays Reata $400M in Expanded Antioxidant Inflammation Modulator Deal
  
• Private-Public Partnership Focusing on Neglected Tropical Diseases Established
  
• Merck & Co. Signs Up Abbott to Develop a Companion Diagnostic for Anticancer Candidate
  
• Abbott Nabs Distribution Rights to Biofortuna’s Freeze-Dried HLA Typing Kits
  
• Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney Injury Drug
  
• IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
  
• Firms Ally to Develop Humira Biosimilar
  
• Abbott, Emergent Terminate Co-Development Deal for B-Cell Cancers
  
• Abbott Pays Galapagos $150M Up Front for Phase II-Stage Rheumatoid Arthritis Drug